Cleveland-Cliffs Q3 2026: Strong EBITDA Recovery, Positive Net Income

What happened

Cleveland-Cliffs reported Q3 2026 revenue of $5.6 billion, shipments of 4.2 million net tons, GAAP net income of $165 million, adjusted EBITDA of $612 million, and adjusted EPS of $0.28, a sharp improvement from Q1 2026 (revenue $4.9B, shipments 4.1M, adjusted EBITDA $95M, net loss $237M). The significant EBITDA expansion and swing to profitability likely reflects tariff-supported pricing, mix improvement, and the positive impact of the company's cost and footprint actions, though the press release does not detail free cash flow or debt movements. Liquidity increased modestly to $3.2 billion from $3.1 billion, providing breathing room. This quarter appears to satisfy key prior thesis checkpoints, including positive cash generation and holding realized pricing, though confirmation of free cash flow and ABL borrowings is needed. The results suggest the operating turnaround is gaining traction, but leverage and external risks remain.

Implication

Investors should view Q3 2026 as a pivotal quarter that likely validates the turnaround thesis, with adjusted EBITDA jumping to $612 million and net income turning positive, but they must confirm that operating cash flow and free cash flow turned decisively positive and that ABL borrowings declined, as those were the original bullish triggers. The sharp improvement likely reflects higher average selling prices, better mix, and the full benefit of the slab contract exit, yet the press release omits unit pricing and cost detail, so it is unclear how much of the gain is sustainable versus one-off. Liquidity of $3.2 billion is adequate but remains tight relative to $7.76 billion of long-term debt, so the company still needs to prove it can self-fund operations and reduce leverage. The stock's rerating will depend on whether management guides to continued positive cash generation in Q4 2026 and beyond, and whether the POSCO transaction or labor agreements introduce new risks. For now, the evidence supports a more constructive stance, but prudent investors should wait for the 10-Q filing to verify cash flow and debt trends before upgrading from WAIT.

Thesis delta

The prior WAIT thesis was conditioned on Q2/Q3 2026 showing positive free cash flow and stable ASP; Q3's reported adjusted EBITDA of $612 million and GAAP net income of $165 million strongly suggest that condition has been met. This shifts the thesis from neutral to cautiously positive, with the key remaining variable being confirmation of free cash flow and debt reduction in the quarterly filing. The implied value should move toward the base-case scenario of around $10.50, with potential upside toward $13.50 if cash conversion is confirmed.